Literature DB >> 15759106

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.

J J Holst1, C F Deacon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15759106     DOI： 10.1007/s00125-005-1705-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  32 in total

1.  Glucagon-like peptide containing pathways in the regulation of feeding behaviour.

Authors:  M Tang-Christensen; N Vrang; P J Larsen
Journal:  Int J Obes Relat Metab Disord       Date:  2001-12

Review 2.  Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

Authors:  R Mentlein
Journal:  Regul Pept       Date:  1999-11-30

3.  Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms.

Authors:  B Balkan; X Li
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2000-10       Impact factor: 3.619

Review 4.  Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

Authors:  J J Holst; C F Deacon
Journal:  Diabetes       Date:  1998-11       Impact factor: 9.461

5.  Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.

Authors:  Juris J Meier; Baptist Gallwitz; Stefan Salmen; Oliver Goetze; Jens J Holst; Wolfgang E Schmidt; Michael A Nauck
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

6.  Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells.

Authors:  Atsushi Nakagawa; Hanae Satake; Hajime Nakabayashi; Makoto Nishizawa; Keisuke Furuya; Shigeru Nakano; Toshikazu Kigoshi; Kohzo Nakayama; Kenzo Uchida
Journal:  Auton Neurosci       Date:  2004-01-30       Impact factor: 3.145

7.  The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.

Authors:  Lise L Kjems; Jens J Holst; Aage Vølund; Sten Madsbad
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

Review 8.  Incretins, insulin secretion and Type 2 diabetes mellitus.

Authors:  T Vilsbøll; J J Holst
Journal:  Diabetologia       Date:  2004-02-13       Impact factor: 10.122

9.  The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide.

Authors:  G S Meneilly; M Bryer-Ash; D Elahi
Journal:  Diabetes Care       Date:  1993-01       Impact factor: 19.112

10.  Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region.

Authors:  D Dardevet; M C Moore; D Neal; C A DiCostanzo; W Snead; A D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-03-16       Impact factor: 4.310
View more
  99 in total

1.  Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.

Authors:  Mansur Shomali
Journal:  Clin Diabetes       Date:  2014-01

Review 2.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 3.  Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling.

Authors:  Charlotte C Ronveaux; Daniel Tomé; Helen E Raybould
Journal:  J Nutr       Date:  2015-02-04       Impact factor: 4.798

4.  What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?

Authors:  B Ahrén
Journal:  Diabetologia       Date:  2005-03-16       Impact factor: 10.122

Review 5.  Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Authors:  M A Nauck; I Vardarli; C F Deacon; J J Holst; J J Meier
Journal:  Diabetologia       Date:  2010-09-25       Impact factor: 10.122

Review 6.  Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?

Authors:  Lin Li
Journal:  Neurosci Bull       Date:  2007-01       Impact factor: 5.203

Review 7.  Neural integration of satiation and food reward: role of GLP-1 and orexin pathways.

Authors:  Diana L Williams
Journal:  Physiol Behav       Date:  2014-03-18

8.  Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.

Authors:  Lene Jessen; Benedikt A Aulinger; Jonathan L Hassel; Kyle J Roy; Eric P Smith; Todd M Greer; Stephen C Woods; Randy J Seeley; David A D'Alessio
Journal:  Endocrinology       Date:  2012-10-02       Impact factor: 4.736

Review 9.  How do different GLP-1 mimetics differ in their actions?

Authors:  Simeon Pierre Choukem; Jean-François Gautier
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

10.  Nucleus accumbens GLP-1 receptors influence meal size and palatability.

Authors:  Amanda M Dossat; Ryan Diaz; Lindsay Gallo; Alyssa Panagos; Kristen Kay; Diana L Williams
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-04-23       Impact factor: 4.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.